基于科学方法统一临床试验与药品标签中的避孕建议
本文介绍EFPIA-PDEG关于临床试验方案和产品标签中避孕建议协调统一的共识,提出基于非临床数据的数据驱动方法。文章指出当前缺乏国际共识导致各地区建议不一,并提出基于遗传毒性和发育毒性数据的基本原理,包括致突变药物通常需要男女避孕,而当暴露 margins 达到10倍或以上时通常不需要避孕。
要点
- 致突变药物通常需要对男女受试者进行避孕。
- 当最大推荐人用剂量暴露与NOAEL暴露的margin≥10倍时,通常不需要避孕(针对纯非整倍体药物和致畸/胚胎致死药物)。
- 临床试验中女性默认避孕,男性避孕可在有适当信息时取消;产品标签仅在必要时推荐避孕。
核心结论
- 提出了基于数据的理由,可作为跨地区临床试验和产品标签中一致避孕建议的基础。
研究设计与样本
- 欧洲制药工业协会联合会/临床前开发专家组(EFPIA-PDEG)主题组的共识综述。
主要发现
- 对于大多数药物,避孕建议通常仅基于非临床数据和/或机制。
- 临床试验中,女性默认避孕并贯穿整个临床开发,而男性避孕可在有适当信息时取消。
- 产品标签中仅在必要时推荐避孕。
- 致突变药物通常需要对男女受试者进行避孕。
- 对于纯非整倍体药物以及引起胎儿畸形或胚胎-胎儿致死的药物,当最大推荐人用剂量暴露与NOAEL暴露的margin为10倍或以上时,通常不需要避孕。
关键数值与推荐
- 当最大推荐人用剂量暴露与NOAEL暴露的margin≥10倍时,通常不需要避孕(针对纯非整倍体药物和致畸/胚胎致死药物)。
临床怎么用
- 在制定临床试验方案和产品标签时,可基于遗传毒性和发育毒性数据评估避孕必要性。
- 对于致突变药物,应考虑男女受试者的避孕措施。
- 当暴露margin≥10倍时,可考虑不推荐避孕(针对特定药物类型)。
局限性
- 文中未报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review presents a European Federation of Pharmaceutical Industries and Association/PreClinical Development Expert Group (EFPIA-PDEG) topic group consensus on a data-driven approach to harmonized contraception recommendations for clinical trial protocols and product labeling. There is no international agreement in pharmaceutical clinical trial protocols or product labeling on when/if female and/or male contraception is warranted and for how long after the last dose. This absence of consensus has resulted in different recommendations among regions. For most pharmaceuticals, contraception recommendations are generally based exclusively on nonclinical data and/or mechanism. For clinical trials, contraception is the default position and is maintained for women throughout clinical development, whereas appropriate information can justify removing male contraception. Conversely, contraception is only recommended in product labeling when warranted. A base case rationale is proposed for whether or not female and/or male contraception is/are warranted, using available genotoxicity and developmental toxicity data. Contraception is generally warranted for both male and female subjects treated with mutagenic pharmaceuticals. We propose as a starting point that contraception is not typically warranted when the margin is 10-fold or greater between clinical exposure at the maximum recommended human dose and exposure at the no observed adverse effect level (NOAEL) for purely aneugenic pharmaceuticals and for pharmaceuticals that induce fetal malformations or embryo-fetal lethality. Other factors are discussed, including contraception methods, pregnancy testing, drug clearance, options for managing the absence of a developmental toxicity NOAEL, drug-drug interactions, radiopharmaceuticals, and other drug modalities. Overall, we present a data-driven rationale that can serve as a basis for consistent contraception recommendations in clinical trials and in product labeling across regions.
引用
- Bowman CJ, Becourt-Lhote N, Boulifard V, et al. Science-Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels. Clin Pharmacol Ther. 2022. PMID: 35388453. doi:10.1002/cpt.2602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。